Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Alphapharm Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

(-) Cancellation by sponsor (813)
ARTG (832)
Prescription medicine registration (58)
Cancellation or suspension (52)
Australian public assessment report (AusPar) (3)
Designation or determination (3)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (1)

Date

2025 (29)
2024 (7)
2023 (60)
2022 (149)
2021 (174)
2020 (48)
2019 (10)
2018 (33)
2017 (299)
2016 (4)

Search

Filters applied:

Cancellation by sponsor

Clear all

Sponsor content

813 result(s) found, displaying 251 to 260

Tobramycin Alphapharm tobramycin 80 mg/2 mL injection, solution vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
Tobramycin Agila tobramycin 80 mg/2 mL injection, solution vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RIVASTIGMELON PATCH 5 rivastigmine 4.6 mg/24 hours transdermal drug delivery system sachet Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RIVASTIGMELON PATCH 10 rivastigmine 9.5 mg/24 hours transdermal drug delivery system sachet Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
DILART HCT 80/12.5 mg valsartan 80 mg/hydrochlorothiazide 12.5 mg film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
DILART HCT 160/12.5 mg valsartan 160 mg/hydrochlorothiazide 12.5 mg film-coated tablet bottle Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
TOPOTECAN CH topotecan (as hydrochloride) 4 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
TOPOTECAN MYLAN topotecan (as hydrochloride) 4 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
PARAPANE PE COLD & FLU DAY AND NIGHT tablets blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
TRAMADOL MYLAN SR tramadol hydrochloride 200mg modified release tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Alphapharm Pty Ltd

Pages

First page
Previous page
…
Page 22
Page 23
Page 24
Page 25
Current page 26
Page 27
Page 28
Page 29
Page 30
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.